

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL


OMB Number: 3235-0076

Expires: August 31, 2015

Estimated Average burden hours per response: 4.0

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s)	<b>▼</b> None	Entity Type
0001651407			© Corporation
Name of Issuer	_		C Limited Partnership
Checkpoint Therapeutics, Inc.			C Limited Liability Company
Jurisdiction of Incorporation/Organization	_		C General Partnership
DELAWARE			C Business Trust
Year of Incorporation/Organization	on		C Other
O Over Five Years Ago			
Within Last Five Years (Specify Year)	2014		
C Yet to Be Formed			

2 Principal Place	of Business and Contact Information
Name of Issuer	of Business and Contact mornation
Checkpoint Therapeutics, In	nc.
Street Address 1	Street Address 2
2 GANSEVOORT STREET	9TH FLOOR
City	State/Province/Country ZIP/Postal Code Phone No. of Issuer
NEW YORK	NEW YORK 10014 212-554-4366



Clarification of Response (if Nec	essary)			
Last Name	First Name		Middle Name	
Horin	David		J.	
Street Address 1		Street Address 2	2	
c/o 2 Gansevoort Street		9th Floor		
City	State/Province/C	Country	ZIP/Postal Code	
New York	NEW YORK		10014	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Response (if Nec	essary)			
Last Name	First Name		Middle Name	
Rosenwald	Lindsay		A.	
Street Address 1		Street Address 2	2	
c/o 2 Gansevoort Street		9th Floor		
City	State/Province/C	Country	ZIP/Postal Code	
New York	NEW YORK		10014	
Relationship:	Executive Officer	<b>☑</b> Director	Promoter	
Clarification of Response (if Nec				
Last Name	First Name		Middle Name	
Herskowitz	Neil			
Street Address 1		Street Address 2	2	
c/o 2 Gansevoort Street		9th Floor		
City	State/Province/C	Country	ZIP/Postal Code	
New York	NEW YORK		10014	
Relationship:	Executive Officer	Director	Promoter	
Clarification of Response (if Nec	essary)			
Last Name	First Name		Middle Name	
Salzman	Barry			
Street Address 1		Street Address 2	2	
c/o 2 Gansevoort Street		9th Floor		
City	State/Province/C	Country	ZIP/Postal Code	
New York	NEW YORK		10014	
Relationship:	Executive Officer	□ Director	Promoter	
Clarification 6.D. 27.55				
Clarification of Response (if Nec	essary)			
i				

Last Name	First Name Middle Name
Boilen	Scott
treet Address 1	Street Address 2
c/o 2 Gansevoort Street	9th Floor
lity	State/Province/Country ZIP/Postal Code
New York	NEW YORK 10014
Relationship: Executi	ive Officer Director Promoter
Clarification of Response (if Necessary	
I. Industry Group	
Agriculture	Health Care C Retailing
Banking & Financial Services	Biotechnology     Health Insurance     Restaurants
C Commercial Banking	C Hospitals & Dhysiaians
C Insurance	C Pharmaceuticals
C Investing	O Other Health Care
C Investment Banking	C Telecommunications
Pooled Investment Fund	Other Technology
Other Banking & Financial  C Services	Travel
	C Manufacturing C Airlines & Airports
Business Services	Real Estate C Lodging & Conventions
Energy Coal Mining	C Commercial C Tourism & Travel Service
C Electric Utilities	C REITS & Finance
C Energy Conservation	C Residential C Other
C Environmental Services	C Other Real Estate
C Oil & Gas	
C Other Energy	
5. Issuer Size	
Revenue Range	Aggregate Net Asset Value Range
No Revenues	No Aggregate Net Asset Value
\$1 - \$1,000,000	\$1 - \$5,000,000
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000	C \$50,000,001 - \$100,000,000
Over \$100,000,000	C Over \$100,000,000
• Decline to Disclose	C Decline to Disclose
C Not Applicable	C Not Applicable
A.A.	A-1000 A
6. Federal Exemption(sapply)	s) and Exclusion(s) Claimed (select all that
Rule 504(b)(1) (not (i), (ii)	Rule 505
or (iii))  Rule 504 (b)(1)(i)	
	▼ Rule 506(b)
Rule 504 (b)(1)(ii)	
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
	Investment Company Act Section 3(c)
=======================================	

7. Type of Filing	
New Notice Date of First Sale	5-09-30 First Sale Yet to Occur
Amendment	
B. Duration of Offering	
oes the Issuer intend this offering to last more that	nn one year? C Yes C No
oes the issuer intent this oriening to last more than	none year.
) T (a) a ( a) a ( a) a ( a) a ( a)	The Land all the formal A
7. Type(s) of Securities Offere	ed (select all that apply)
Interests Equity	
Tenant-in-Common Securities Debt	Warrant or Other Right to
Acquire	Another Security
Security to be Acquired Upon  Exercise of Option, Warrant or Other (d	describe)
Other Right to Acquire Security	
IO Business Cambin the T	
0. Business Combination Tra	
this offering being made in connection with a bus ansaction, such as a merger, acquisition or exchan	
arification of Response (if Necessary)	
11. Minimum Investment	
linimum investment accepted from any outside vestor	\$ 0 USD
(VCStO)	
2. Sales Compensation	
Recipient	Recipient CRD Number None
National Securities Corporation	7569
Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD None
National Securities Corporation	7569
Street Address 1	Street Address 2
410 Park Avenue	14th Floor
City	State/Province/Country ZIP/Postal Code
New York	NEW YORK 10022
tate(s) of Solicitation	☐ Foreign/Non-US
<ol><li>Offering and Sales Amoun</li></ol>	nts
otal Offering Amount \$ 62500000	USD   Indefinite
otal Amount Sold \$ 57817000	USD
otal Remaining to be s 4683000	USD   Indefinite

Clarific	ation of Response (if Necessary)
14. I	nvestors
	Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,  Number of such non-accredited investors who already have invested in the offering
	Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
15. 8	Sales Commissions & Finders' Fees Expenses
	e separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an iture is not known, provide an estimate and check the box next to the amount.
	Sales Commissions \$ 5781700 USD Estimate
	Finders' Fees \$ 0 USD Estimate
Clarific	ation of Response (if Necessary)
of the	lition to the cash commission above, Issuer also issued warrants to purchase a number of shares Issuer's Common Stock equal to 10% of the aggregate amount of shares into which the Notes in the offering eventually are convertible.
16. l	Jse of Proceeds
any of t	the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to he persons required to be named as executive officers, directors or promoters in response to Item 3 above. mount is unknown, provide an estimate and check the box next to the amount.  S  USD  Estimate
Clarific	ation of Response (if Necessary)
Other and ot benefi	than the payment of salaries ther compensation and ts, no officer, director or tota will receive any payments

promoter will receive any payments from the proceeds of this offering.

## Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

## **Terms of Submission**

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Checkpoint Therapeutics, Inc.	/s/ James F. Oliviero, III	James F. Oliviero,	President and Chief Executive Officer	2016-09-08